Moderna's Norovirus Vaccine Enters Final Testing

Moderna's mRNA vaccine for norovirus, the first of its kind, is set to enter final testing stages, potentially reducing the burden of the virus that causes about 12,000 hospitalizations annually in the UK. Norovirus, which leads to gastroenteritis, is highly contagious and often spreads in close-contact environments like schools and hospitals. The ongoing Phase 3 trial, dubbed Nova 301, aims to enroll 25,000 participants globally, focusing on older adults. Meanwhile, wastewater surveillance in California has shown promise in accurately tracking norovirus outbreaks, highlighting its potential as a vital tool in public health. Recent figures from Wales indicate a significant rise in norovirus cases, with a 118% increase reported in one week, emphasizing the need for public awareness and hygiene measures. Experts recommend thorough handwashing, as alcohol gels may not be effective against norovirus.